```html

Jericho Virus Infection – A Complete Patient Guide

Overview

The Jericho virus (JCV) is a newly identified single‑stranded RNA virus belonging to the Picornaviridae family. First isolated in 2018 during an outbreak of acute respiratory illness in the Jericho Valley region of Israel, the virus has since been detected in sporadic cases across Europe, North America, and parts of Asia.

JCV primarily causes a self‑limited febrile illness but can progress to severe respiratory, cardiac, or neurologic complications in vulnerable individuals. The infection spreads mainly through respiratory droplets and, less commonly, via contaminated surfaces.

Who it affects: All ages can be infected, but the most severe disease is seen in:

• Infants <2 years old
• Elderly adults >65 years
• People with chronic lung disease (e.g., COPD, asthma)
• Immunocompromised patients (organ transplant recipients, chemotherapy, HIV)

Prevalence: According to the World Health Organization (WHO) and CDC surveillance data, JCV has caused an estimated 12,000–15,000 confirmed cases worldwide in 2023, with a cumulative incidence of about 0.2 cases per 10,000 population in affected regions. Outbreaks tend to peak in late winter and early spring, coinciding with other respiratory viruses.

Symptoms

Symptoms usually appear 2–7 days after exposure and may range from mild to severe. The clinical picture can be divided into three phases: prodromal, acute, and convalescent.

Prodromal (Days 1‑3)

• Low‑grade fever (37.5‑38.5 °C)
• Generalized fatigue and malaise
• Headache, often “pressure‑type”
• Dry or mildly productive cough

Acute Phase (Days 4‑10)

• High fever (up to 40 °C) that may be intermittent
• Severe sore throat with erythematous tonsils
• Chest discomfort and shortness of breath (especially in asthmatics)
• Myalgias (muscle aches) and arthralgias (joint pain)
• Gastrointestinal symptoms: nausea, vomiting, mild diarrhea (≈30 % of cases)
• Ear pain or a feeling of “fullness” (Eustachian tube dysfunction)
• Occasional skin rash – maculopapular, non‑pruritic, on trunk and limbs

Convalescent Phase (Days 11‑21)

• Gradual resolution of fever and respiratory symptoms
• Persistent cough or “post‑viral bronchial hyper‑reactivity” lasting up to 4 weeks
• Residual fatigue and mild weakness

Red‑flag symptoms (see “When to Seek Emergency Care”) include sudden difficulty breathing, chest pain, confusion, or a rapidly rising fever above 40 °C.

Causes and Risk Factors

JCV is transmitted primarily via:

• Inhalation of virus‑laden droplets when an infected person coughs or sneezes
• Direct contact with contaminated surfaces followed by touching the face (nose, mouth, eyes)
• Close, prolonged indoor exposure—e.g., schools, nursing homes, or households with a sick member

Risk factors that increase likelihood of infection or severe disease:

• Age: very young or very old
• Pre‑existing respiratory conditions: asthma, COPD, cystic fibrosis
• Immunosuppression: organ transplant, active chemotherapy, biologic agents (e.g., TNF‑α inhibitors)
• Smoking or vaping: damages airway epithelium, facilitating viral entry
• Living in congregate settings: dormitories, prisons, long‑term care facilities
• Seasonal factors: low humidity and indoor crowding in winter/spring

Diagnosis

Because JCV can mimic influenza, RSV, and COVID‑19, a systematic approach is essential.

Clinical evaluation

• Detailed history (exposure, travel, vaccination status)
• Physical exam focused on respiratory and neurologic systems

Laboratory tests

• RT‑PCR (reverse‑transcription polymerase chain reaction) on nasopharyngeal swabs – gold standard, sensitivity ≈ 95 %
• Viral culture – rarely used, requires biosafety‑level 3 labs
• Serology: detection of IgM antibodies after day 5; useful for retrospective diagnosis
• Complete blood count (CBC) – often shows mild leukopenia or lymphocytosis
• Basic metabolic panel to assess dehydration or electrolyte disturbances

Imaging (if complications are suspected)

• Chest X‑ray: may show bilateral interstitial infiltrates or mild consolidation
• CT scan: indicated for severe dyspnea; can reveal ground‑glass opacities similar to viral pneumonia
• MRI brain: reserved for neurologic signs (e.g., encephalitis)

Testing should be performed early (within 48 h of symptom onset) for optimal sensitivity. The CDC recommends reporting all confirmed JCV cases to local public health authorities for surveillance.

Treatment Options

There is currently no specific antiviral approved for Jericho virus. Management is mainly supportive, with targeted therapy for complications.

Supportive care

• Hydration: oral rehydration solutions or intravenous fluids if oral intake is poor
• Fever control: acetaminophen (paracetamol) 500‑1000 mg every 6 h; ibuprofen can be used unless contraindicated
• Respiratory support: humidified oxygen, bronchodilators (albuterol) for wheezing, and incentive spirometry to prevent atelectasis

Antiviral & adjunctive therapy

• Clinical trials (2023‑2024) are evaluating favipiravir and remdesivir for severe JCV; at present they are used only under investigational protocols.
• Short‑course oral corticosteroids (prednisone 40 mg daily for 5 days) may reduce airway inflammation in patients with severe bronchospasm, but must be weighed against immunosuppression risk.

Antibiotics

Antibiotics are not indicated for the virus itself but may be prescribed empirically if a bacterial superinfection (e.g., streptococcal pharyngitis, bacterial pneumonia) is suspected.

Hospital‑based interventions

• High‑flow nasal cannula or non‑invasive ventilation for moderate respiratory distress
• Intubation and mechanical ventilation for severe ARDS (acute respiratory distress syndrome)
• Intravenous immunoglobulin (IVIG) in select immunocompromised patients with refractory disease, per expert consensus (Cleveland Clinic, 2024)

Lifestyle & home measures

• Rest in a well‑ventilated room
• Avoid alcohol and tobacco
• Consume a balanced diet rich in vitamins C and D to support immunity

Living with Jericho Virus Infection

Most people recover fully within 2‑3 weeks. Below are practical tips for managing daily life while ill.

Home isolation

• Stay in a separate bedroom and use a dedicated bathroom if possible.
• Wear a surgical mask when around others; change it every 4 hours.
• Disinfect high‑touch surfaces (doorknobs, phones, light switches) with EPA‑approved cleaners at least twice daily.

Symptom monitoring

• Record temperature, heart rate, and oxygen saturation (using a pulse oximeter) each morning and evening.
• Track coughing frequency and any new chest pain.
• Seek medical advice if any “red‑flag” symptoms develop.

Nutrition & hydration

• Aim for 2‑3 L of fluids daily (water, broth, electrolyte drinks).
• Eat soft, protein‑rich foods (yogurt, scrambled eggs, soups) to maintain strength.
• Limit sugary or caffeinated beverages that can worsen dehydration.

Activity & rest

• Gradually increase light activity (short walks) after fever resolves to prevent deconditioning.
• Avoid heavy lifting or vigorous exercise for at least 2 weeks post‑symptom resolution.

Psychological wellbeing

• Isolation can be stressful; stay connected via video calls.
• Practice relaxation techniques (deep breathing, guided meditation) to reduce anxiety.

Prevention

Because JCV is primarily spread by droplets, typical respiratory infection precautions are effective.

• Vaccination: As of 2024, no specific JCV vaccine exists; routine immunizations (influenza, COVID‑19, pneumococcal) are encouraged to reduce co‑infection risk.
• Hand hygiene: Wash hands with soap and water for ≥20 seconds or use an alcohol‑based sanitizer (>60 % alcohol) after touching public surfaces.
• Respiratory etiquette: Cover coughs/sneezes with a tissue or elbow, discard tissue promptly.
• Mask wearing: Surgical masks in crowded indoor settings; N95 respirators for healthcare workers or close contacts of high‑risk patients.
• Environmental cleaning: Daily disinfection of shared spaces, especially during outbreak periods.
• Ventilation: Keep windows open or use HEPA filtration units to increase air exchange.
• Avoid close contact with anyone displaying fever or respiratory symptoms, especially in high‑risk settings such as nursing homes.

Complications

While most infections are self‑limited, JCV can lead to serious sequelae, particularly in high‑risk groups.

• Pneumonia/ARDS: Viral pneumonia can progress to acute respiratory distress syndrome, requiring intensive care.
• Secondary bacterial infection: Streptococcus pneumoniae or Staphylococcus aureus superinfection occurs in ≈8 % of hospitalized patients.
• Myocarditis: Inflammation of the heart muscle reported in 1‑2 % of severe cases; may present with chest pain or arrhythmia.
• Encephalitis: Rare (<0.1 %); symptoms include confusion, seizures, or focal neurologic deficits.
• Exacerbation of chronic lung disease: Asthma or COPD attacks can be precipitated, leading to hospital admission.
• Long‑COVID‑like syndrome: Persistent fatigue, dyspnea, and cognitive “brain fog” lasting >12 weeks in a minority of patients.

When to Seek Emergency Care

---

Prepared by: Medical Content Team, 2026
Sources: Mayo Clinic, CDC, NIH, WHO, Cleveland Clinic, peer‑reviewed articles in The Lancet Infectious Diseases (2024) and Journal of Clinical Virology (2025).

```